Literature DB >> 6305264

Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation.

J R Wingard, A D Hess, R K Stuart, R Saral, W H Burns.   

Abstract

Toxicity to hematopoiesis and lymphocytic function are major considerations in the clinical applicability of antiviral agents. We have examined the toxicities of five antiviral agents showing activity against herpesviruses: vidarabine, acyclovir, (E)-5-(2-bromovinyl)-2'-deoxyuridine, trifluorothymidine, and (S)-9-(2,3-dihydroxypropyl)adenine. The drugs were tested in vitro for inhibition of herpes simplex virus type 1 and human cytomegalovirus replication, effects on marrow progenitor cell growth, effects on lymphocyte responses to mitogen and alloantigen stimulation, and effects on several lymphocyte cytotoxic responses. In general, lymphocyte proliferative responses were inhibited by the various drugs at lower concentrations than were cytotoxic activities. Acyclovir and (E)-5-(2-bromovinyl)-2'-deoxyuridine were the least toxic drugs tested, with antiviral indices exceeding 10,000. Vidarabine and trifluorothymidine were more toxic, with antiviral indices generally between 10 and 100. (S)-9-(2,3-dihydroxypropyl)-adenine was the most toxic, with several antiviral indices between 1 and 10.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305264      PMCID: PMC184707          DOI: 10.1128/AAC.23.4.593

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Prophylactic adenine arabinoside following marrow transplantation.

Authors:  K G Kraemer; P E Neiman; W C Reeves; E D Thomas
Journal:  Transplant Proc       Date:  1978-03       Impact factor: 1.066

2.  Fluorinated pyrimidines. XLIV. Interaction of 5-trifluoromethyl-2'-deoxyuridine 5'-triphosphate with deoxyribonucleic acid polymerases.

Authors:  H Tone; C Heidelberger
Journal:  Mol Pharmacol       Date:  1973-11       Impact factor: 4.436

3.  HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients.

Authors:  G V Quinnan; N Kirmani; E Esber; R Saral; J F Manischewitz; J L Rogers; A H Rook; G W Santos; W H Burns
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

4.  Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients.

Authors:  G V Quinnan; N Kirmani; A H Rook; J F Manischewitz; L Jackson; G Moreschi; G W Santos; R Saral; W H Burns
Journal:  N Engl J Med       Date:  1982-07-01       Impact factor: 91.245

5.  Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro.

Authors:  R W McGuffin; F M Shiota; J D Meyers
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

6.  Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

Authors:  E de Clercq; H Degreef; J Wildiers; G de Jonge; A Drochmans; J Descamps; P de Somer
Journal:  Br Med J       Date:  1980-11-01

7.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

8.  Cellular immune responses to herpesviruses during treatment with adenine arabinoside.

Authors:  R W Steele; R E Keeney; J Brown; E J Young
Journal:  J Infect Dis       Date:  1977-04       Impact factor: 5.226

9.  Cytotoxicity by cultured human lymphocytes: characteristics of effector cells and specificity of cytotoxicity.

Authors:  J R Ortaldo; G D Bonnard; P D Kind; R B Herberman
Journal:  J Immunol       Date:  1979-04       Impact factor: 5.422

10.  Acyclovir prophylaxis of herpes-simplex-virus infections.

Authors:  R Saral; W H Burns; O L Laskin; G W Santos; P S Lietman
Journal:  N Engl J Med       Date:  1981-07-09       Impact factor: 91.245

View more
  8 in total

1.  Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2.

Authors:  J Balzarini; C Zhu; E De Clercq ; M J Pérez-Pérez; C Chamorro; M J Camarasa; A Karlsson
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

2.  Hypomethylating drugs efficiently decrease cytosine methylation in telomeric DNA and activate telomerase without affecting telomere lengths in tobacco cells.

Authors:  Eva Majerová; Miloslava Fojtová; Iva Mozgová; Miroslava Bittová; Jiří Fajkus
Journal:  Plant Mol Biol       Date:  2011-08-25       Impact factor: 4.076

3.  Comparison of flow cytometric analysis and [3H]thymidine incorporation for measurement of the effects of drug toxicity on lymphocyte stimulation.

Authors:  D J Marmer; R W Steele
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

4.  In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans.

Authors:  R E Dornsife; D R Averett
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on proliferation of human fibroblasts, peripheral blood mononuclear cells, and granulocyte-monocyte progenitor cells in vitro.

Authors:  A E Wittek; P S Cohen; A M Arvin; S D Smith; C M Koropchak; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

6.  Oral BVDU treatment of varicella and zoster in children with cancer.

Authors:  Y Benoit; G Laureys; M J Delbeke; E De Clercq
Journal:  Eur J Pediatr       Date:  1985-01       Impact factor: 3.183

7.  Antiviral therapy can reverse the development of immune senescence in elderly mice with latent cytomegalovirus infection.

Authors:  Mark Beswick; Annette Pachnio; Sarah N Lauder; Clive Sweet; Paul A Moss
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

8.  Acyclovir Therapy Reduces the CD4+ T Cell Response against the Immunodominant pp65 Protein from Cytomegalovirus in Immune Competent Individuals.

Authors:  Annette Pachnio; Jusnara Begum; Ashini Fox; Paul Moss
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.